Skip to main
ANL

ANL Stock Forecast & Price Target

ANL Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Adlai Nortye is a promising clinical-stage company with a strong pipeline, including the promising drug AN9025 as a competitor to other RAS inhibitors. However, there are risks involved in funding and pipeline failures, as well as potential side effects and valuation challenges. Overall, the company's progress in business development and the FDA approval of the study for AN4035 support a positive outlook, but investors must carefully consider the associated risks.

Bears say

Adlai Nortye is a clinical-stage company with a promising pipeline of drug candidates in the areas of RAS-targeting therapies and next-generation cancer immunotherapies. While there is a large addressable market for RAS-driven cancers, there are concerns about AN9025's clinical validation and potential toxicity issues due to its high affinity and long half-life. The asymmetric market cap differential between Adlai Nortye and its competitors also highlights the uncertainty surrounding their valuation and commercial success.

ANL has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Adlai Nortye Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Adlai Nortye Ltd (ANL) Forecast

Analysts have given ANL a Strong Buy based on their latest research and market trends.

According to 5 analysts, ANL has a Strong Buy consensus rating as of Sep 28, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Adlai Nortye Ltd (ANL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.